Science & TechnologyImportant2025-02-14

CDSCO Mandates Phase III Trial for Baloxavir

In News

What Happened

The Subject Expert Committee (SEC) on Antimicrobial and Antiviral drugs, under the Central Drugs Standard Control Organization (CDSCO), rejected Roche Products India’s request for a waiver of local clinical trials for Baloxavir Marboxil (brand name Xofluza) during its meeting on 13-14 February 2025. The committee mandated that Phase III clinical trials must be conducted in the Indian population before the drug can receive marketing approval. The SEC concluded that acute uncomplicated influenza does not constitute an unmet medical need in India, and therefore the conditions for granting a trial waiver under the New Drugs and Clinical Trials Rules, 2019 were not met.

Why It Matters

This decision reinforces India’s regulatory sovereignty in drug approval, affirming that foreign approvals alone are insufficient for marketing permission. It highlights the CDSCO’s mandate that drugs must demonstrate safety and efficacy specifically in the Indian population before widespread use, especially when the condition being treated already has existing treatment options.

Background

History & Context

Baloxavir Marboxil is a first-in-class cap-dependent endonuclease inhibitor that targets the polymerase acidic (PA) protein of the influenza virus, blocking the "cap-snatching" mechanism essential for viral mRNA synthesis. Unlike neuraminidase inhibitors such as Oseltamivir (Tamiflu), which prevent viral release from host cells, Baloxavir inhibits viral replication at an earlier stage. The drug was first approved in Japan in 2018 and subsequently in the US, Canada, and Australia. Under India’s New Drugs and Clinical Trials Rules, 2019 (Rule 101), the Drugs Controller General of India (DCGI) may waive local Phase III trials for drugs already approved in specified countries, but only when conditions such as unmet medical need or absence of alternative therapies are satisfied.

What Changed

▶
The SEC rejected Roche’s re-deliberation request for a clinical trial waiver, finding that sufficient Indian patient data was not available to justify bypassing local trials.
▶
Phase III clinical trials in the Indian population were mandated as a prerequisite for import and marketing approval of Baloxavir Marboxil tablets.
▶
The committee explicitly determined that acute uncomplicated influenza is not an unmet medical need in India, given the availability of existing treatments like Oseltamivir.
▶
This decision set a precedent that drugs approved in major regulatory jurisdictions (US, Japan, EU) are not automatically exempt from Indian clinical validation requirements.

Prelims Angle

NCERT Connection

Class 12 Biology (Chapter 8: Human Health and Disease) introduces the concepts of immunity, infectious diseases, and drug mechanisms. Baloxavir Marboxil illustrates how antiviral drugs can target specific viral enzymes rather than broadly suppressing the immune response. The drug’s mechanism of inhibiting cap-dependent endonuclease in the viral RNA polymerase complex connects to the molecular biology concepts of mRNA processing and gene expression covered in NCERT.

Practice Questions

Q1

With Reference To

With reference to Baloxavir Marboxil, consider the following statements: 1. It inhibits the neuraminidase enzyme of the influenza virus. 2. It was rejected for marketing in India because the drug failed efficacy trials abroad. 3. The CDSCO’s Subject Expert Committee mandated Phase III trials in the Indian population. Which of the statements given above is/are correct?

Up next